Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Non Operating Investment Income for 4 consecutive years, with $25991.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Investment Income rose 166.64% to $25991.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59050.0 through Dec 2025, up 254.89% year-over-year, with the annual reading at $59050.0 for FY2025, 254.89% up from the prior year.
  • Non Operating Investment Income for Q4 2025 was $25991.0 at Inhibikase Therapeutics, up from -$1245.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $36281.0 in Q1 2025, with the low at -$167536.0 in Q2 2023.
  • Average Non Operating Investment Income over 4 years is -$10746.5, with a median of $776.0 recorded in 2024.
  • Peak annual rise in Non Operating Investment Income hit 1455.29% in 2025, while the deepest fall reached 354.77% in 2025.
  • Over 4 years, Non Operating Investment Income stood at $26828.0 in 2022, then plummeted by 94.14% to $1571.0 in 2023, then crashed by 2582.62% to -$39002.0 in 2024, then skyrocketed by 166.64% to $25991.0 in 2025.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at $25991.0, -$1245.0, and -$1977.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.